FDA OKs 23andMe to market genetic testing for risk of 10 ailments
Washington — For the first time, U.S. regulators have authorized a company to tell consumers directly about their individual genetic risk of certain diseases and conditions without involving a health care professional.
The California-based company 23andMe gained approval from the Food and Drug Administration to market genetic testing for risk of 10 ailments, including Parkinson's and Alzheimer's diseases.
The FDA, which in 2013 blocked the company from providing genetic health information, announced its decision Thursday.
The agency said the new tests may help people make decisions about lifestyle and help them have informed discussions with health care professionals. But it cautioned that genetic risk is just one piece of information, and it does not mean they will eventually get a disease or not.
Please Log In to add a comment.
Latest for Insiders
- Score one for RTP: CEO explains why he bolted Silicon Valley for the Triangle
- Dr. James Goodnight, part 2: Advice on overcoming adversity, his proudest SAS memories, and the Triangle's bright future
- NC Biz Wire, PACES team, Google Fiber advocate land WRAL TechWire Editor's Choice Awards
- TechWire Awards go to six individual, six corporate Triangle tech, life science leaders
- Dr. James Goodnight: From moment of inspiration to building SAS, a global software powerhouse
- With all tickets gone, TechWire Awards to be streamed live at WRAL.com
- As Scot Wingo's new gig Spiffy lands extra $2.5M, he 'loves' being back with a startup
- Dr. Charles Hamner: A creator of NC's life science industry
- First WRAL TechWire Hall of Famers: Five pillars of NC's tech success
- Why Red Hat's new CFO left IBM - and what he likes better